About Mitochondrial amidoxime-reducing component 1
Mitochondrial amidoxime-reducing component 1 (MTARC1) is a protein
from Homo sapiens identified by UniProt accession
Q5VT66, 337 residues long.
MolForge cross-references it against 0 known binders and
137 disease associations.
Target properties
| Protein name | Mitochondrial amidoxime-reducing component 1 |
| UniProt accession | Q5VT66 |
| Gene | MTARC1 |
| Organism | Homo sapiens |
| Length | 337 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (137)
Diseases linked to this target (Open Targets).
- low density lipoprotein cholesterol measurement · score 0.49
- high density lipoprotein cholesterol measurement · score 0.49
- total cholesterol measurement · score 0.48
- vitamin D measurement · score 0.47
- alkaline phosphatase measurement · score 0.47
- serum alanine aminotransferase measurement · score 0.47
- sex hormone-binding globulin measurement · score 0.46
- triglyceride measurement · score 0.46
- alcohol consumption measurement · score 0.45
- alcohol drinking · score 0.45
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q5VT66-F1 | alphafold | PREDICTED | 91.29 | — |
Amino-acid sequence (337 residues)
MGAAGSSALA RFVLLAQSRP GWLGVAALGL TAVALGAVAW RRAWPTRRRR LLQQVGTVAQ LWIYPVKSCK GVPVSEAECT AMGLRSGNLR DRFWLVINQE GNMVTARQEP RLVLISLTCD GDTLTLSAAY TKDLLLPIKT PTTNAVHKCR VHGLEIEGRD CGEATAQWIT SFLKSQPYRL VHFEPHMRPR RPHQIADLFR PKDQIAYSDT SPFLILSEAS LADLNSRLEK KVKATNFRPN IVISGCDVYA EDSWDELLIG DVELKRVMAC SRCILTTVDP DTGVMSRKEP LETLKSYRQC DPSERKLYGK SPLFGQYFVL ENPGTIKVGD PVYLLGQ
Explore Mitochondrial amidoxime-reducing component 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets